On May 27, 2025, MAIA Biotechnology, Inc. secured approximately $695,000 through a private placement of 429,999 shares and warrants at $1.50 each, to fund its phase II trial THIO-101. The deal includes participation from a company director who subscribed for $50,000 worth of shares.